Big Bear Pharma Announces Approval of Six Anti-Cancer Targeted Drugs in Laos

Date:2023-05-03 Views: 489 Times

Vientiane, Laos - April 28, 2023 - Big Bear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative therapies for cancer, announced today that it has received approval from the Ministry of Health of Laos for six anti-cancer targeted drugs.

The approved drugs are:

  1. Dabrafenib: sold under the brand name DABRADX among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.
  2. Trametinib:sold under the brand name TRAMEDX among others, is an anticancer medication used for the treatment of melanoma. It is a MEK inhibitor drug with anti-cancer activity. It inhibits MEK1 and MEK2. It is taken by mouth.
  3. Lorlatinib:  sold under the brand name LORLADX, It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.
  4. Capmatinib: sold under the brand name CAMPMAD, is an anticancer medication used for the treatment of metastatic non-small cell lung cancer whose tumors have a mutation that leads to the exon 14 skipping of the MET gene, which codes for the membrane receptor HGFR.
  5. Gilteritinib: sold under the brand name GILLIDX, is an anti-cancer drug. It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor. 
  6. Ruxolitinib: sold under the brand name RUSODX , is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease.Ruxolitinib is a Janus kinase inhibitor.

The approval of these drugs marks a significant milestone for Big Bear Pharma and its mission to bring innovative and effective treatments to patients with cancer in Laos and beyond. The company plans to launch the drugs in the local market in the coming months and to expand its presence in the Southeast Asian region.

“We are thrilled to receive the approval of our six anti-cancer targeted drugs in Laos, which demonstrates our commitment to delivering cutting-edge therapies to patients in need,” said Nipaporn Khunkaw, CEO of Big Bear Pharma. “We are grateful to the Ministry of Health of Laos for their support and collaboration throughout the regulatory process. We look forward to working with them and other stakeholders to ensure the accessibility and affordability of our drugs for the people of Laos.”

About Big Bear Pharma

Big Bear Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for cancer. The company has a diverse pipeline of anti-cancer targeted drugs that address various molecular pathways and mechanisms of action. Big Bear Pharma aims to improve the lives of patients with cancer by providing them with more options, better outcomes and lower costs. 

Forward-Looking Statements

To the extent applicable laws and regulations, expressions such as "plan," "target," "expect," "forecast," and similar expressions appearing in this press release are forward-looking statements. The forward-looking statements set forth herein involve a number of risks and uncertainties that may differ materially from actual results. Important factors leading to such differences include, but are not limited to, changes in regulations and/or economic conditions, uncertainty in clinical research results, exposure to various market risks, and other factors beyond the control of the company.